Delivery Order SPE2DB22D3501-SPE2DB24FWE22
Award Date
7/5/24
Potential Completion Date
7/26/24
Potential Value
$1.2K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the provision of ZOLADEX 3.6 MG IMPLANT SYRNS, a pharmaceutical product, to the Defense Logistics Agency (DLA). The award, valued at $1,873.74, is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical division, valued at up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $3,509.16 to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the federal government. The contract is for the delivery of ZOLADEX 10.8 MG IMPLANT SYRNS, with a completion date of June 13, 2024. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office division is for the delivery of ZOLADEX 3.6 MG IMPLANT SYRNS, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract is a Delivery Order with a Firm Fixed Price pricing type, and has a ceiling value of $1,873.74. The contract does not have a set-aside designation. Amerisourcebergen is a major pharmaceutical distributor that has been awarded numerous federal contracts, often serving as a...
This is a federal contract award by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of 4,565,606,804 units of the pharmaceutical product ZOLADEX 10.8 MG IMPLANT SYRNS. The contract has a firm fixed price ceiling value of $1,754.58 and an ultimate completion date of September 17, 2024. AmerisourceBergen, a major supplier of pharmaceutical products and medical supplies to the U.S. government, has been awarded this delivery order contract without any set-aside...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of ZOLADEX 3.6 MG IMPLANT SYRNS. The contract, valued at $1,873.74, is a Firm Fixed Price Delivery Order with a completion date of September 16, 2024. Amerisourcebergen, through its Corporate Office division, is the prime contractor for this award, which does not have a set-aside designation. The contract is part of...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation, is a firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical valued at $1,249.20. The award is for the delivery of ZOLADEX 3.6 MG IMPLANT SYRNS, a specialized pharmaceutical product, with a completion date of March 22, 2024. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside designation for...
This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading pharmaceutical sourcing and distribution services company. The contract is a delivery order with a firm fixed price valued at $1,561.45, for the supply of ZOLADEX 3.6 MG IMPLANT SYRNS, a specialty pharmaceutical product. The contract has an ultimate completion date of April 24, 2024 and was awarded on April 3,...
This federal contract award is for the delivery of ZOLADEX 3.6 MG IMPLANT SYRNS, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $1,561.45 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor that serves the U.S. federal government. The contract has an ultimate completion date of July 8, 2024 and is not associated with a set-aside designation. Amerisourcebergen holds a larger Indefinite...
This federal contract award, valued at $1,873.74, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of the pharmaceutical product ZOLADEX 3.6 MG IMPLANT SYRNS, with a completion date of May 10, 2024. Amerisourcebergen, a large pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to...
This federal contract award, valued at $1,292.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ZOLADEX 3.6 MG IMPLANT SYRNS, a specialty medication. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for...